Fig. 4
Prognostic value of angiogenic biomarkers. The association between a less profound reduction in Tie2 and higher Ktrans:VEGFR2 ratio (Fig. 2b) identified a poor prognostic group. The WTV derived from DCI-MRI of this poor prognostic group (dotted lines) was compared with better prognostic outcome group (solid lines). a Shows the differential impact of single agent bevacizumab (10 mg/kg) on WTV between the two groups up to 15 days after treatment, with effects emerging by day 4 (P = 0.029, Mann–Whitney U test). b Volumetric analysis showed persistence of this difference throughout the course of combined cytotoxic chemotherapy and bevacizumab, with changes in WTV plotted using the same groups against the percentage time that elapsed between randomization and the date of progression/censoring (%PFS; P = 0.012, Mann–Whitney U test). Error bars indicate the standard error. WTV; whole tumor volume, DCE-MRI; dynamic contrast-enhanced magnetic resonance imaging, VEGFR2; vascular endothelial growth factor receptor 2, PFS; progression-free survival
